Company patents

SHIONOGI & CO., LTD.

SHIONOGI & CO., LTD. shows a surprising shift in its patent strategy, with a significant decline in its core "Pharmaceutical Preparations" category, which represents 65.6% of its portfolio, experiencing a -31.2% year-over-year drop in 2026 so far. While "Therapeutic Activity (Pharma)" remains stable at 10 patents so far in 2026, the company is also seeing a notable decline in "Peptides & Proteins" with a -100.0% YoY drop in 2026 after a 150.0% growth in 2025, suggesting a potential re-evaluation of its R&D focus within the pharma_biotech sector.

Patent Trend by Technology Area

Yearly patent publications since 2023

Product themes

Product-level themes inferred from filings since 2023, with category chips showing where each theme appears. Select a theme to filter the patents below.

96 US filings (since 2023) · 10 categories · 16 themes

Targeted Small Molecule Therapeutics

Design and synthesis of acyclic or carbocyclic organic compounds that selectively modulate specific biological targets or pathways for the treatment of diseases.

Heterocyclic Compounds (Pharma)Pharmaceutical PreparationsAcyclic / Carbocyclic Compounds
Who else files here? →
41since 2023
-50.0%YoY
Nucleic Acid-Based Therapies

Therapeutic strategies employing nucleic acids (DNA, RNA, oligonucleotides) to modulate gene expression, deliver genetic material, or interfere with disease-causing pathways. Includes gene therapy using viral vectors.

Therapeutic Activity (Pharma)Pharmaceutical Preparations
Who else files here? →
14since 2023
-80.0%YoY
Targeted Drug Formulation Delivery

Delivery systems specifically engineered to administer advanced drug formulations (e.g., microparticles, biologics, extended-release systems) to achieve precise targeting, controlled release kinetics, or enhanced therapeutic efficacy within the body.

Pharmaceutical Preparations
Who else files here? →
11since 2023
-60.0%YoY
Drug Candidate Synthesis

Methods and intermediates for preparing complex organic molecules intended as active pharmaceutical ingredients (APIs), often involving multi-step synthesis and optimization of reaction pathways.

General Organic Chemistry Methods
Who else files here? →
8since 2023
+100.0%YoY
Chemical Synthesis of Drug Intermediates

Processes and methodologies for the efficient and scalable preparation of complex heterocyclic compounds and their precursors, including specific reaction conditions, purification techniques, and intermediate compounds.

Heterocyclic Compounds (Pharma)
Who else files here? →
7since 2023
0.0%YoY
Advanced Biomarker Detection Assays

Methods and compositions for identifying, quantifying, or characterizing specific biological molecules (e.g., nucleic acids, proteins, metabolites, antibodies) or microbial species, often for diagnostic, prognostic, or quality control applications.

Material & Chemical Analysis
Who else files here? →
5since 2023
+200.0%YoY
API Solid Form Engineering

Techniques for preparing and characterizing specific solid forms, such as crystal forms, salts, co-crystals, or amorphous forms, of active pharmaceutical ingredients to optimize properties like stability, solubility, and bioavailability.

Heterocyclic Compounds (Pharma)General Organic Chemistry Methods
Who else files here? →
4since 2023
0.0%YoY
Antibody Engineering & Therapeutics

Design and modification of antibodies or antibody-derived fragments for targeted therapeutic intervention, including bispecific formats, Fc region modifications, and activatable constructs.

Pharmaceutical PreparationsTherapeutic Activity (Pharma)Peptides & ProteinsMaterial & Chemical Analysis
Who else files here? →
3since 2023
+100.0%YoY
Targeted Protein Degradation

Development of small molecules, often bifunctional (e.g., PROTACs) or molecular glues, that induce the ubiquitin-proteasome system or autophagy to selectively degrade specific disease-causing proteins.

Heterocyclic Compounds (Pharma)
Who else files here? →
3since 2023
+100.0%YoY
Advanced Drug Delivery Systems

Development of lipid-based nanoparticles, liposomes, or other molecular platforms to encapsulate and deliver therapeutic agents, particularly nucleic acids, to target tissues or improve pharmacokinetics.

Acyclic / Carbocyclic Compounds
Who else files here? →
3since 2023
n/a
Advanced Cell & Gene Therapies

Development of therapeutic approaches involving the genetic modification of cells (e.g., T cells, stem cells, macrophages) or the use of viral/non-viral vectors to deliver genetic material for disease treatment.

Pharmaceutical PreparationsPeptides & Proteins
Who else files here? →
2since 2023
+100.0%YoY
Cellular Immunotherapy

Therapeutic approaches involving the use of living cells, often genetically modified or ex vivo activated, to treat diseases, particularly cancer, by modulating immune responses or replacing damaged cells.

Therapeutic Activity (Pharma)
Who else files here? →
2since 2023
n/a
Immune Checkpoint Modulation

Therapeutic interventions that target immune checkpoint pathways to either enhance or suppress immune responses, often used in cancer immunotherapy or autoimmune diseases.

Therapeutic Activity (Pharma)
Who else files here? →
2since 2023
n/a
Wearable Physiological Sensing

Development of devices and methods for non-invasive or minimally invasive collection and analysis of physiological data, often from wearable sensors, to monitor health, activity, or specific conditions.

Medical Diagnostics & Surgery
Who else files here? →
1since 2023
new
Protein & Peptide Engineering

Modification of protein or peptide sequences, structures, or post-translational modifications (e.g., glycosylation, lipidation) to enhance their stability, solubility, delivery, or therapeutic efficacy.

Peptides & Proteins
Who else files here? →
1since 2023
new
AI for Medical Diagnostics

Utilizing machine learning, particularly deep learning, to analyze medical data such as images, sensor readings, or physiological signals for disease prediction, diagnosis, or treatment assessment.

Healthcare Informatics
Who else files here? →
1since 2023
new

Patents

Showing 1-10 of 156

Page 1 of 16
US 12637443 B2GRANTED
C07D401/12

Cyclic amine derivatives having serotonin receptor binding activity

Filed:2021-12-27Pub:2026-05-26
Applicant:Shionogi & Co., Ltd.

Provided are a compound having serotonin 5-HT2A receptor antagonism and/or inverse agonism, a pharmaceutically acceptable salt thereof, and a composition for serotonin 5-HT2A receptor antagonism and/or inverse agonism comprising them. A compound represented by Formula (I): wherein R 1 is substituted or unsubstituted aromatic heterocyclyl or the like; R 2 is each independently a hydrogen atom or the like; R 3 is each independently a hydrogen atom or the like; n is 1 or the like; a combination of (L 1 , L 2 ) is (NH, N) or the like; R 4 is a group represented by Formula: wherein p and q are each independently 2 or the like; R a is substituted or unsubstituted alkyl or the like; X b is each independently CR b R b′ ; R b is each independently a hydrogen atom or the like; R b′ is each independently a hydrogen atom or the like; X c is each independently CR c R c′ ; R c is each independently a hydrogen atom or the like; R c′ is each independently a hydrogen atom or the like; X d is CR d or the like; and R d is a hydrogen atom or the like; R 5 and R 6 are each independently a hydrogen atom or the like; and R 7 is a group represented by Formula: wherein A is CR 11 or the like; R 9 is substituted or unsubstituted alkyloxy or the like; R 10 is a hydrogen atom or the like; and R 11 is each independently a hydrogen atom or the like; or a pharmaceutically acceptable salt thereof.